1. Home
  2. CRON vs GERN Comparison

CRON vs GERN Comparison

Compare CRON & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cronos Group Inc.

CRON

Cronos Group Inc.

HOLD

Current Price

$2.73

Market Cap

985.8M

Sector

Health Care

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.27

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRON
GERN
Founded
N/A
1990
Country
Canada
United States
Employees
N/A
258
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
985.8M
808.3M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
CRON
GERN
Price
$2.73
$1.27
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$2.17
AVG Volume (30 Days)
1.6M
14.2M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$146,587,000.00
N/A
Revenue This Year
$26.34
$26.91
Revenue Next Year
$15.53
$43.75
P/E Ratio
$68.38
N/A
Revenue Growth
24.63
N/A
52 Week Low
$1.84
$1.04
52 Week High
$3.43
$2.01

Technical Indicators

Market Signals
Indicator
CRON
GERN
Relative Strength Index (RSI) 53.81 35.09
Support Level $2.47 $1.24
Resistance Level $2.72 $1.29
Average True Range (ATR) 0.10 0.09
MACD 0.00 -0.02
Stochastic Oscillator 39.23 14.29

Price Performance

Historical Comparison
CRON
GERN

About CRON Cronos Group Inc.

Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: